Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi‐eligible countries

作者
Emily A. Burger,Allison Portnoy,Nicole G. Campos,Stephen Sy,Catherine Regan,Jane J. Kim
出处
期刊:International Journal of Cancer [Wiley]
卷期号:148 (4): 932-940 被引量:43
标识
DOI:10.1002/ijc.33233
摘要

The human papillomavirus (HPV) vaccines may provide some level of cross-protection against high-risk HPV genotypes not directly targeted by the vaccines. We evaluated the long-term health and economic impacts of routine HPV vaccination using either the nonavalent HPV vaccine or the bivalent HPV vaccine in the context of 48 Gavi-eligible countries. We used a multi-modeling approach to compare the bivalent with or without cross-protection and the nonavalent HPV vaccine. The optimal, that is, most cost-effective, vaccine was the vaccine with an incremental cost-effectiveness ratio below the per-capita gross domestic product (GDP) for each country. By 2100 and assuming 70% HPV vaccination coverage, a bivalent vaccine without cross-protection, a bivalent vaccine with favorable cross-protection and the nonavalent vaccine were projected to avert 14.9, 17.2 and 18.5 million cumulative cases of cervical cancer across all 48 Gavi-eligible countries, respectively. The relative value of the bivalent vaccine compared to the nonavalent vaccine increased assuming a bivalent vaccine conferred high cross-protection. For example, assuming a cost-effectiveness threshold of per-capita GDP, the nonavalent vaccine was optimal in 83% (n = 40) of countries if the bivalent vaccine did not confer cross-protection; however, the proportion of countries decreased to 63% (n = 30) if the bivalent vaccine conferred high cross-protection. For lower cost-effectiveness thresholds, the bivalent vaccine was optimal in a greater proportion of countries, under both cross-protection assumptions. Although the nonavalent vaccine is projected to avert more cases of cervical cancer, the bivalent vaccine with favorable cross-protection can prevent a considerable number of cases and would be considered a high-value vaccine for many Gavi-eligible countries.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
放青松完成签到 ,获得积分10
1秒前
橘子海完成签到 ,获得积分10
1秒前
lulala完成签到,获得积分10
2秒前
YoungLee完成签到 ,获得积分10
3秒前
wdufhgk发布了新的文献求助10
3秒前
KisaragiSabrina完成签到,获得积分10
4秒前
cdercder的应助被小小木采纳,获得10
4秒前
4秒前
manman完成签到 ,获得积分10
5秒前
徐院长完成签到,获得积分10
6秒前
乐无忧完成签到 ,获得积分10
6秒前
7秒前
徐院长发布了新的文献求助10
10秒前
华仔的应助被霖29采纳,获得10
10秒前
洁净的天德完成签到,获得积分10
11秒前
马佳闯完成签到 ,获得积分10
14秒前
future完成签到 ,获得积分10
14秒前
14秒前
152455完成签到 ,获得积分10
15秒前
蝉鸣一夏完成签到,获得积分10
15秒前
流觞曲水完成签到 ,获得积分10
17秒前
破事不糊墙完成签到,获得积分10
17秒前
犹豫大树完成签到,获得积分10
17秒前
XL完成签到,获得积分10
19秒前
guac完成签到,获得积分10
20秒前
007完成签到 ,获得积分10
21秒前
友好的晓曼完成签到,获得积分10
23秒前
清风明月完成签到,获得积分10
23秒前
sky完成签到,获得积分10
24秒前
2580852qwe完成签到 ,获得积分10
24秒前
我看看sci怎么个事完成签到 ,获得积分10
26秒前
keyIncy完成签到,获得积分10
27秒前
徐妮完成签到,获得积分10
28秒前
29秒前
暗心不语完成签到,获得积分10
29秒前
lianxin完成签到 ,获得积分10
29秒前
30秒前
32秒前
rayqiang完成签到,获得积分0
32秒前
一笑没的应助被科研通管家采纳,获得10
33秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185571
求助须知:如何正确求助?哪些是违规求助? 9574290
关于积分的说明 21834928
捐赠科研通 7783274
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558973
邀请新用户注册赠送积分活动 2481370